CSBio CSBio

X
[{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz\u00ae Immunotherapy Product in Rheumatoid Arthritis Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and IASO Biotherapeutics Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"IASO Bio"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"WuXi Biologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, WuXi will provide comprehensive CMC development and current cGMP manufacturing services for IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, to treat Immune-Mediated Inflammatory Diseases.

            Lead Product(s): TNAX101A

            Therapeutic Area: Immunology Product Name: IMB1001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: IMIDomics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CAN106 is a clinical-stage investigational novel, long-acting recombinant humanized monoclonal antibody that binds to and neutralizes C5, a key component of the complement system.

            Lead Product(s): CAN106

            Therapeutic Area: Immunology Product Name: CAN106

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IASO Bio has the right of first negotiation to develop and commercialize Cabaletta’s products including CABA-201, using the licensed sequence in the Greater China region.

            Lead Product(s): CABA-201

            Therapeutic Area: Immunology Product Name: CABA-201

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Cabaletta Bio

            Deal Size: $162.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ImmCelz® utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. Creative Medical Technology conducted studies showed efficacy of its ImmCelz® immunotherapy product in the collage induced model of rheumatoid arthritis.

            Lead Product(s): ImmCelz

            Therapeutic Area: Immunology Product Name: ImmCelz

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY